The development of targeted therapy in epidermal growth factor receptor (EGFR)-mutated
non-small cell lung cancer (NSCLC) patients has radically changed their clinical …

Osimertinib is currently the preferred first-line therapy in patients with non-small cell lung
cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutation and the …

Targeted therapy with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-
TKIs) is the standard first-line treatment for advanced EGFR-mutated non-small cell lung …

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …

The introduction of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
has significantly improved the prognosis of advanced non-small cell lung cancer (NSCLC) …

Simple Summary Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is currently indicated as first-line therapy in patients with non-small …

The use of epidermal growth factor receptor (EGFR) inhibitors such as osimertinib has
improved outcomes and quality of life for patients with EGFR-mutated non-small cell lung …

Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the …

Osimertinib, a third-generation EGFR TKI, is the standard therapy for previously untreated
EGFR-mutated non-small cell lung cancer patients following the landmark FLAURA study …

The discovery of activating mutations in epidermal growth factor receptor (EGFR) in non-
small-cell lung cancer transformed the care and prognosis of patients and heralded the era …